Free Trial

22,855 Shares in Nature's Sunshine Products, Inc. (NASDAQ:NATR) Acquired by Mackenzie Financial Corp

Nature's Sunshine Products logo with Medical background

Key Points

  • Mackenzie Financial Corp has acquired a stake in Nature's Sunshine Products, buying 22,855 shares valued at approximately $287,000, representing about 0.12% of the company.
  • Nature's Sunshine Products reported $0.35 earnings per share, exceeding analysts' expectations of $0.16, while achieving quarterly revenue of $114.75 million.
  • Major shareholder Fosun Pharmaceutical Shanghai sold 2,854,607 shares at an average price of $11.46, totaling over $32.7 million in transactions.
  • Need better tools to track Nature's Sunshine Products? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Mackenzie Financial Corp acquired a new stake in shares of Nature's Sunshine Products, Inc. (NASDAQ:NATR - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 22,855 shares of the company's stock, valued at approximately $287,000. Mackenzie Financial Corp owned approximately 0.12% of Nature's Sunshine Products at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in NATR. GAMMA Investing LLC boosted its stake in Nature's Sunshine Products by 2,090.2% in the 1st quarter. GAMMA Investing LLC now owns 2,234 shares of the company's stock worth $28,000 after purchasing an additional 2,132 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Nature's Sunshine Products during the fourth quarter worth $41,000. Deutsche Bank AG acquired a new position in Nature's Sunshine Products in the fourth quarter valued at $103,000. Wells Fargo & Company MN raised its holdings in shares of Nature's Sunshine Products by 28.8% during the fourth quarter. Wells Fargo & Company MN now owns 7,209 shares of the company's stock valued at $106,000 after purchasing an additional 1,611 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Nature's Sunshine Products by 346.9% during the fourth quarter. BNP Paribas Financial Markets now owns 11,719 shares of the company's stock worth $172,000 after acquiring an additional 9,097 shares in the last quarter. 79.40% of the stock is owned by institutional investors and hedge funds.

Nature's Sunshine Products Stock Performance

NATR stock traded up $0.31 during trading on Wednesday, reaching $16.59. The company had a trading volume of 28,272 shares, compared to its average volume of 61,330. The company has a market cap of $292.49 million, a price-to-earnings ratio of 22.35 and a beta of 1.14. The firm has a 50-day simple moving average of $15.01 and a 200-day simple moving average of $14.00. Nature's Sunshine Products, Inc. has a twelve month low of $11.01 and a twelve month high of $18.06.

Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.16 by $0.19. Nature's Sunshine Products had a net margin of 3.06% and a return on equity of 10.19%. The business had revenue of $114.75 million during the quarter, compared to analyst estimates of $113.10 million.

Insider Activity at Nature's Sunshine Products

In related news, major shareholder Fosun Pharmaceutical Shanghai sold 2,854,607 shares of Nature's Sunshine Products stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $11.46, for a total value of $32,713,796.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.60% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on NATR. DA Davidson reiterated a "buy" rating and issued a $19.00 target price on shares of Nature's Sunshine Products in a research note on Tuesday, June 3rd. Canaccord Genuity Group increased their target price on shares of Nature's Sunshine Products from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, August 1st.

Read Our Latest Stock Report on Nature's Sunshine Products

Nature's Sunshine Products Company Profile

(Free Report)

Nature's Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.

Further Reading

Institutional Ownership by Quarter for Nature's Sunshine Products (NASDAQ:NATR)

Should You Invest $1,000 in Nature's Sunshine Products Right Now?

Before you consider Nature's Sunshine Products, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nature's Sunshine Products wasn't on the list.

While Nature's Sunshine Products currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Soaring Valuation—Justified or Overhyped?
3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines